284 related articles for article (PubMed ID: 19670917)
1. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.
Ing-Lorenzini K; Desmeules J; Plachta O; Suva D; Dayer P; Peter R
Drug Saf; 2009; 32(9):775-85. PubMed ID: 19670917
[TBL] [Abstract][Full Text] [Related]
2. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
[TBL] [Abstract][Full Text] [Related]
3. Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails.
Egol KA; Park JH; Rosenberg ZS; Peck V; Tejwani NC
Clin Orthop Relat Res; 2014 Sep; 472(9):2728-34. PubMed ID: 23604648
[TBL] [Abstract][Full Text] [Related]
4. Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up.
Png MA; Mohan PC; Koh JSB; Howe CY; Howe TS
Osteoporos Int; 2019 Dec; 30(12):2417-2428. PubMed ID: 31435684
[TBL] [Abstract][Full Text] [Related]
5. Alendronate-associated femoral insufficiency fractures and femoral stress reactions.
Wang K; Moaveni A; Dowrick A; Liew S
J Orthop Surg (Hong Kong); 2011 Apr; 19(1):89-92. PubMed ID: 21519086
[TBL] [Abstract][Full Text] [Related]
6. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.
Weil YA; Rivkin G; Safran O; Liebergall M; Foldes AJ
J Trauma; 2011 Jul; 71(1):186-90. PubMed ID: 21610533
[TBL] [Abstract][Full Text] [Related]
7. Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases.
Ballas EG; Mavrogenis AF; Karamanis E; Kokkalis ZT; Mitsiokapa E; Koulalis D; Mastrokalos D; Papagelopoulos PJ
Eur J Orthop Surg Traumatol; 2015 Jan; 25(1):181-7. PubMed ID: 24676887
[TBL] [Abstract][Full Text] [Related]
8. Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.
Patel VC; Lazzarini AM
Orthopedics; 2010 Oct; 33(10):775. PubMed ID: 20954650
[TBL] [Abstract][Full Text] [Related]
9. Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed!
Rydholm A
Acta Orthop; 2012 Aug; 83(4):319-20. PubMed ID: 22900912
[No Abstract] [Full Text] [Related]
10. Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment.
Yeh WL; Su CY; Chang CW; Chen CH; Fu TS; Chen LH; Lin TY
BMC Musculoskelet Disord; 2017 Dec; 18(1):527. PubMed ID: 29237448
[TBL] [Abstract][Full Text] [Related]
11. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series.
Sasaki S; Miyakoshi N; Hongo M; Kasukawa Y; Shimada Y
J Bone Miner Metab; 2012 Sep; 30(5):561-7. PubMed ID: 22610061
[TBL] [Abstract][Full Text] [Related]
12. [Subtrochanteric pathological fracture on bisphosphonates].
Mathonet PY; Willems S; Ciornohac JF
Rev Med Liege; 2018 Feb; 73(2):56-60. PubMed ID: 29517866
[TBL] [Abstract][Full Text] [Related]
13. Outcomes between older adults with atypical and typical femoral fractures are comparable.
Khow KS; Paterson F; Shibu P; Yu SC; Chehade MJ; Visvanathan R
Injury; 2017 Feb; 48(2):394-398. PubMed ID: 27839798
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-associated femur fractures have high complication rates with operative fixation.
Prasarn ML; Ahn J; Helfet DL; Lane JM; Lorich DG
Clin Orthop Relat Res; 2012 Aug; 470(8):2295-301. PubMed ID: 22669553
[TBL] [Abstract][Full Text] [Related]
15. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.
Puhaindran ME; Farooki A; Steensma MR; Hameed M; Healey JH; Boland PJ
J Bone Joint Surg Am; 2011 Jul; 93(13):1235-42. PubMed ID: 21776577
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy.
Lim HS; Kim CK; Park YS; Moon YW; Lim SJ; Kim SM
J Bone Joint Surg Am; 2016 Dec; 98(23):1978-1987. PubMed ID: 27926679
[TBL] [Abstract][Full Text] [Related]
17. Can long-term bisphosphonate use causes low-energy fractures? A case report.
Dandinoğlu T; Akarsu S; Karadeniz M; Tekin L; Arıbal S; Kıralp MZ
Osteoporos Int; 2014 Feb; 25(2):773-6. PubMed ID: 23824297
[TBL] [Abstract][Full Text] [Related]
18. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study.
Lim SJ; Yeo I; Yoon PW; Yoo JJ; Rhyu KH; Han SB; Lee WS; Song JH; Min BW; Park YS
Osteoporos Int; 2018 Nov; 29(11):2427-2435. PubMed ID: 30039251
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Sánchez A; Blanco R
Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
